No quarterly revenue total was found in REVIVA PHARMACEUTICALS HOLDINGS, INC.'s SEC filings.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $19.9 million in cash and investments and $144,093 in total debt.
Revenue
—
Net income
$-2.45M
+59.6% vs year-ago quarter
Operating cash flow
$-2.12M
+57.8% vs year-ago quarter
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
13.11M
-80.7% vs year-ago quarter
Net cash
$19.75M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RVPH (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cupertino, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1742927
- Former names
- Tenzing Acquisition Corp. (until Dec 14, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$2.6M | -$3.3M | -$3.6M | -$4.0M | -$6.1M |
| Net income | -$2.4M | -$3.2M | -$3.4M | -$4.0M | -$6.1M |
| Operating cash flow | -$2.1M | -$3.8M | -$5.8M | -$5.6M | -$5.0M |
| Total assets | $21.1M | $23.6M | $15.9M | $14.3M | $11.6M |
| Total liabilities | $5.9M | $6.1M | $7.3M | $9.8M | $12.1M |
| Stockholders' equity | $15.2M | $17.4M | $8.6M | $4.5M | -$459,147 |
| Cash and investments | $19.9M | $22.2M | $14.4M | $13.2M | $10.4M |
| Total debt | $144,093 | $231,274 | $406,875 | $0 | $113,246 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 13, 2026 | May 13, 2026 |
| 8-K |
Current report
Listing notice, Other events
|
May 13, 2026 | May 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 15, 2026 | Apr 15, 2026 |
All 413 Reviva Pharmaceuticals Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.